leadf
logo-loader
viewTodos Medical Ltd.

Todos Medical signs distribution deal with Aditx Therapeutics for COVID-19 immunity monitoring service

Blood samples will be collected by Todos or its partner networks and sent to Aditxt’s AditxtScore Center for processing, with service expected to begin in January 2021

Todos Medical Ltd. -
Todos Medical says Aditx’s AditxtScore is the most comprehensive immune profiling tool for COVID-19 available in the market

Todos Medical Ltd (OTCQB:TOMDF) announced on Monday that it has signed an agreement with Aditx Therapeutics Inc (NASDAQ:ADTX), through which it has secured the rights to distribute Aditx’s immune-related AditxtScore COVID-19 scoring sytem, with planned availability in January 2021. 

The company noted that blood samples will be collected by Todos and/or its network of partners and sent to Aditxt’s CLIA accredited AditxtScore Center for processing, with planned service availability expected early next year. 

“After a thorough review of the immune-related COVID-19 testing market, we believe that Aditxt’s platform technology represents a unique multidimensional view of the immune system that will be critical to allow physicians and scientists to categorize immune responses to vaccines and therapeutic approaches for COVID-19 in order to determine which interventions to use for which patients in a personalized way,” said Todos Medical CEO Gerald Commissiong in a statement.   

READ: Todos Medical has developed the technological tools for early disease detection 

He added: “As vaccines for COVID-19 are rolled out, it is imperative that we evaluate patients’ immune status prior to and after vaccination, and track when immunity is gained and how long it might last with repeat immune testing. The AditxtScore for COVID-19 scoring system will initially include antibody and neutralizing antibodies, and will soon include T-cell and B-cell responses as well, which makes it the most comprehensive immune profiling tool for COVID-19 available in the market.”

Aditx Therapeutics CEO Amro Albanna also weighed in on the deal, stating: “This agreement marks a milestone for AditxtScoreand Aditxt as a whole. Todos Medical is Aditxt’s first commercial customer for our proprietary AditxtScore immune monitoring platform and its first application, AditxtScorefor COVID-19. As the availability of COVID-19 vaccines increases, the need to understand an individual’s immune profile to measure its effectiveness, increases as well. We look forward to working with the team at Todos and providing our innovative AditxtScore platform as a complement to the suite of testing solutions that they offer.”

Todos Medical, which provides the tools necessary for the early detection of life-threatening diseases such as cancer and COVID-19, recently reported $3.2 million in sales for November 2020, up 269% from October 2020 driven by increasing demand for the company’s PCR COVID-19 testing solutions.   

Contact Sean at sean@proactiveinvestors.com

Quick facts: Todos Medical Ltd.

Price: 0.049 USD

OTCQB:TOMDF
Market: OTCQB
Market Cap: $9.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Todos Medical Ltd. named herein, including the promotion by the Company of Todos Medical Ltd. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Todos Medical receives a $3.4 million strategic investment from Yozma Group...

Todos Medical Ltd. (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive the in vitro diagnostics company has received a $3.4 million strategic investment from tech-focused venture capital firm Yozma Group Korea. Commissiong says Todos intends to use the proceeds from the Investment...

on 01/25/2021

2 min read